Pentwater Capital Management LP has recently announced that it has increased stake in Renalytix Plc ADR (NASDAQ:RNLX) by 19.69%. After grabbing 0.6 million shares, the institutional investor is now in possession of 98440.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.23% having worth around $0.28 million. Moreover, Allspring Global Investments LLC increased its share by 0.34 million to have a control over 0.34 million shares. And Corient Private Wealth LLC raised its holdings to 0.11 million shares by acquiring 0.34 million shares or 0.69% of the stake.
Renalytix Plc ADR (RNLX) concluded trading on 01/10/24 at a closing price of $0.34, with 3.25 million shares of worth about $1.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -91.45% during that period and on Wednesday the price saw a loss of about -14.94%. Currently the company’s common shares owned by public are about 46.89M shares, out of which, 46.30M shares are available for trading.
JNL Multi-Manager Small Cap Growt, Leadersel – Innotech ESG, and Balaguer 98 de Inversiones, SICAV are the top 3 mutual funds which are holding stakes in Renalytix Plc ADR JNL Multi-Manager Small Cap Growt is currently holding 0.13 million shares of worth totaling $60060.0. The company recently came buying 0.13 million shares which brought its stake up to 0.26% of the company’s outstanding shares. Leadersel – Innotech ESG sold 7725.0 shares, after which its hold over company’s outstanding shares shrunk to 0.19%, leaving 92275.0 shares with the mutual fund that have a worth of about $43831.0. Balaguer 98 de Inversiones, SICAV, after buying 30002.0 shares, have now control over 0.06% of the stake in the company. It holds 15633.0 shares of worth $14251.0.
Renalytix Plc ADR (NASDAQ: RNLX) started trading at $0.374, below -$0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 0.3798, or with a loss of -14.94%. Stock saw a price change of -25.48% in past 5 days and over the past one month there was a price change of -22.09%. Year-to-date (YTD), RNLX shares are showing a performance of -12.10% which decreased to -86.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $4.04 during that period. The average intraday trading volume for Renalytix Plc ADR shares is 129.97K. The stock is currently trading -15.08% below its 20-day simple moving average (SMA20), while that difference is down -40.93% for SMA50 and it goes to -81.99% lower than SMA200.
Pentwater Capital Management LP acquired 0.6 million shares of Renalytix Plc ADR having value of about $0.28 million. Data submitted at the U.S SEC by Pentwater Capital Management LP revealed that the firm now holds 98440.0 shares in the company valued at close to $33469.6, or have control over 19.69% stake in the company. Renalytix Plc ADR (NASDAQ: RNLX) currently have 46.89M outstanding shares and institutions hold larger chunk of about 17.81% of that. Holding of mutual funds in the company is about 0.61% while other institutional holders and individual stake holders have control over 17.65% and — of the stake respectively.
The stock has a current market capitalization of $17.13M and its 3Y-monthly beta is at 2.11. It has posted earnings per share of -$1.01 in the same period. It has Quick Ratio of 1.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNLX, volatility over the week remained 10.33% while standing at 15.62% over the month.
Analysts are in expectations that Renalytix Plc ADR (RNLX) stock would likely to be making an EPS of $Renalytix plc in the current quarter, while forecast for next quarter EPS is $0.34 and it is $Stocks for next year. For the current quarter EPS, analysts have given the company a lowest target $RLX Technology Inc. which is $RELX PLC PLC at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $Genelux Corporation in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 32.75% while it is estimated to increase by 29.72% in next year.
Analysts at 3 brokerage firms have issued recommendations for the Renalytix Plc ADR (RNLX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 3 Wall Street analysts, 3 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on January 18, 2022 offering a Buy rating for the stock and assigned a target price of $30 to it.
